Synergistic anticancer effect of combination of AZD6244 and BYL719 targeting KRAS mutant in non-small cell lung cancer

被引：0
|
作者：
Jho, Eun Hye [1 ]
Kang, Sin I. [1 ]
Bae, Yeon-Hee [1 ]
Park, Young Mee [1 ]
Sun, Jong-Mu [2 ]
Ahn, Jin Seok [2 ]
Park, Keunchil [2 ]
Ahn, Myung-Ju [2 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4453
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines
    Garon, Edward B.
    Finn, Richard S.
    Hosmer, Wylie
    Dering, Judy
    Ginther, Charles
    Adhami, Shahriar
    Kamranpour, Naeimeh
    Pitts, Sharon
    Desai, Amrita
    Elashoff, David
    French, Tim
    Smith, Paul
    Slamon, Dennis J.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (07) : 1985 - 1994
  • [22] The role of EphA2 in KRAS mutant non-small cell lung cancer
    Amato, Katherine
    Wang, Shan
    Hastings, Andrew
    Chen, Haiying
    Colvin, Daniel
    Ye, Fei
    Chen, Jin
    MOLECULAR CANCER RESEARCH, 2014, 12
  • [23] Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer
    Aredo, J.
    Padda, S.
    Kunder, C.
    Han, S.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1133 - S1133
  • [24] Molecular mechanisms driving oncogenesis in KRAS mutant non-small cell lung cancer
    Holderfield, Matthew
    McCormick, Frank
    Nagel, Tobi
    CANCER RESEARCH, 2010, 70
  • [25] Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer
    Gutierrez Sainz, L.
    Villamayor, J.
    Higuera, O.
    Cruz Castellanos, P.
    Vinal Lozano, D.
    Esteban Rodriguez, I.
    Regojo, R. M.
    Pelaez Garcia, A.
    Heredia Soto, V.
    Mendiola, M.
    Rosas Alonso, R.
    Rodriguez Antolin, C.
    Ibanez de Caceres, I.
    de Castro Carpeno, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S620 - S621
  • [26] KRAS-Mutant non-small cell lung cancer: From biology to therapy
    Ferrer, Irene
    Zugazagoitia, Jon
    Herbertz, Stephan
    John, William
    Paz-Ares, Luis
    Schmid-Bindert, Gerald
    LUNG CANCER, 2018, 124 : 53 - 64
  • [27] A role of nicotinamide phosphoribosyltransferase in growth of KRAS mutant non-small cell lung cancer
    Okumura, Shunsuke
    Sasaki, Takaaki
    Ohsaki, Yoshinobu
    CANCER RESEARCH, 2015, 75
  • [28] Mutant KRAS decouples glycolysis from cell mechanics in non-small cell lung cancer
    Park, Jin Suk
    Sudderth, Jessica
    Gao, Boning
    Bachoo, Robert
    Danuser, Gaudenz
    CANCER RESEARCH, 2017, 77
  • [29] A mechanism of the synergistic effect of combination therapy afatinib with cetuximab in non-small cell lung cancer
    Kobayashi, Keigo
    Ooashi, Ayano
    Yasuda, Hiroyuki
    Hamamoto, Jyunko
    Tani, Tetsuo
    Kawada, Ichiro
    Naoki, Katsuhiko
    Soejima, Kenzo
    Betsuyaku, Tomoko
    CANCER SCIENCE, 2018, 109 : 735 - 735
  • [30] Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer
    Wang, Yifan
    Li, Nan
    Jiang, Wen
    Deng, Weiye
    Ye, Rui
    Xu, Cai
    Qiao, Yawei
    Sharma, Amrish
    Zhang, Ming
    Hung, Mien-Chie
    Lin, Steven H.
    CLINICAL CANCER RESEARCH, 2018, 24 (22) : 5744 - 5756
12345